Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatitis B | 6 | 2024 | 705 | 2.970 |
Why?
|
Measles | 6 | 2022 | 183 | 2.830 |
Why?
|
HIV Infections | 42 | 2024 | 17352 | 2.760 |
Why?
|
Measles-Mumps-Rubella Vaccine | 5 | 2022 | 72 | 2.090 |
Why?
|
Rubella | 3 | 2022 | 55 | 2.030 |
Why?
|
Hepatitis B, Chronic | 4 | 2024 | 410 | 1.990 |
Why?
|
Mumps | 3 | 2022 | 71 | 1.960 |
Why?
|
Travel | 6 | 2024 | 796 | 1.550 |
Why?
|
Cost-Benefit Analysis | 21 | 2024 | 5492 | 1.200 |
Why?
|
HIV Integrase Inhibitors | 2 | 2020 | 165 | 1.100 |
Why?
|
Anti-Retroviral Agents | 7 | 2024 | 1784 | 1.090 |
Why?
|
Hepatitis B virus | 6 | 2024 | 528 | 0.810 |
Why?
|
Quarantine | 1 | 2024 | 181 | 0.790 |
Why?
|
Drug Resistance, Viral | 3 | 2020 | 862 | 0.780 |
Why?
|
CD4 Lymphocyte Count | 4 | 2017 | 2571 | 0.770 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2023 | 289 | 0.730 |
Why?
|
Vaccination | 5 | 2023 | 3384 | 0.720 |
Why?
|
Patient Isolation | 1 | 2020 | 100 | 0.680 |
Why?
|
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2023 | 225 | 0.670 |
Why?
|
Sarcoma, Kaposi | 1 | 2022 | 374 | 0.650 |
Why?
|
Rheumatic Diseases | 3 | 2021 | 649 | 0.650 |
Why?
|
Substance Abuse, Intravenous | 1 | 2023 | 529 | 0.630 |
Why?
|
Point-of-Care Systems | 3 | 2017 | 1213 | 0.630 |
Why?
|
Policy | 1 | 2022 | 508 | 0.610 |
Why?
|
Inappropriate Prescribing | 1 | 2021 | 211 | 0.610 |
Why?
|
Life Expectancy | 6 | 2024 | 1242 | 0.600 |
Why?
|
Anti-Bacterial Agents | 8 | 2021 | 7407 | 0.510 |
Why?
|
Exanthema | 4 | 2018 | 503 | 0.510 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2022 | 2199 | 0.500 |
Why?
|
Anti-HIV Agents | 7 | 2024 | 4527 | 0.490 |
Why?
|
Communicable Disease Control | 4 | 2024 | 846 | 0.490 |
Why?
|
beta-Lactamases | 3 | 2006 | 304 | 0.480 |
Why?
|
South Africa | 10 | 2024 | 1843 | 0.480 |
Why?
|
Hepatitis C | 1 | 2024 | 1584 | 0.460 |
Why?
|
Homosexuality, Male | 6 | 2024 | 1334 | 0.450 |
Why?
|
Drug Resistance, Multiple, Bacterial | 3 | 2010 | 587 | 0.450 |
Why?
|
Viral Load | 2 | 2024 | 3332 | 0.430 |
Why?
|
Hepatitis B e Antigens | 2 | 2024 | 133 | 0.420 |
Why?
|
Outpatients | 1 | 2021 | 1597 | 0.420 |
Why?
|
Klebsiella Infections | 4 | 2007 | 146 | 0.400 |
Why?
|
United States | 28 | 2024 | 72335 | 0.400 |
Why?
|
Enterobacteriaceae | 2 | 2010 | 161 | 0.390 |
Why?
|
Humans | 87 | 2024 | 761572 | 0.380 |
Why?
|
Adrenal Insufficiency | 1 | 2013 | 194 | 0.380 |
Why?
|
Drug Monitoring | 1 | 2017 | 962 | 0.380 |
Why?
|
Health Resources | 2 | 2014 | 935 | 0.370 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2024 | 2297 | 0.370 |
Why?
|
Dementia | 2 | 2024 | 2689 | 0.370 |
Why?
|
HIV Protease Inhibitors | 1 | 2013 | 432 | 0.370 |
Why?
|
Arthralgia | 1 | 2015 | 461 | 0.370 |
Why?
|
Adrenal Glands | 1 | 2013 | 552 | 0.360 |
Why?
|
Oseltamivir | 1 | 2011 | 75 | 0.360 |
Why?
|
Pituitary Gland | 1 | 2013 | 635 | 0.360 |
Why?
|
Escherichia coli Infections | 4 | 2007 | 518 | 0.340 |
Why?
|
Antiviral Agents | 3 | 2024 | 3060 | 0.330 |
Why?
|
Smoking Cessation | 4 | 2024 | 2057 | 0.330 |
Why?
|
beta-Lactams | 1 | 2010 | 155 | 0.320 |
Why?
|
Klebsiella | 2 | 2007 | 49 | 0.320 |
Why?
|
Enterobacteriaceae Infections | 1 | 2010 | 188 | 0.310 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3358 | 0.310 |
Why?
|
Hypothalamus | 1 | 2013 | 999 | 0.300 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4319 | 0.300 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2011 | 445 | 0.280 |
Why?
|
Male | 40 | 2024 | 360842 | 0.280 |
Why?
|
beta-Lactam Resistance | 1 | 2007 | 73 | 0.280 |
Why?
|
Influenza, Human | 2 | 2023 | 1521 | 0.270 |
Why?
|
Mozambique | 2 | 2017 | 55 | 0.270 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2014 | 942 | 0.270 |
Why?
|
DNA, Viral | 2 | 2024 | 2202 | 0.270 |
Why?
|
Hypertension | 3 | 2024 | 8540 | 0.260 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 3206 | 0.260 |
Why?
|
Adult | 33 | 2024 | 221203 | 0.260 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1779 | 0.260 |
Why?
|
Female | 42 | 2024 | 392686 | 0.260 |
Why?
|
Klebsiella oxytoca | 1 | 2005 | 7 | 0.260 |
Why?
|
Dyslipidemias | 2 | 2024 | 868 | 0.250 |
Why?
|
Fluoroquinolones | 1 | 2007 | 307 | 0.250 |
Why?
|
Hepatitis B Surface Antigens | 2 | 2024 | 294 | 0.250 |
Why?
|
Mass Screening | 6 | 2024 | 5428 | 0.250 |
Why?
|
Computer Simulation | 7 | 2024 | 6241 | 0.240 |
Why?
|
Refusal to Participate | 1 | 2024 | 31 | 0.240 |
Why?
|
HIV | 2 | 2023 | 1582 | 0.240 |
Why?
|
South Carolina | 1 | 2024 | 100 | 0.230 |
Why?
|
Health Care Costs | 7 | 2022 | 3242 | 0.230 |
Why?
|
Dideoxynucleosides | 1 | 2024 | 135 | 0.230 |
Why?
|
Adrenal Cortex Hormones | 1 | 2013 | 1881 | 0.230 |
Why?
|
Drug Resistance, Bacterial | 2 | 2010 | 1048 | 0.230 |
Why?
|
Cross Infection | 2 | 2010 | 1422 | 0.230 |
Why?
|
Klebsiella pneumoniae | 1 | 2005 | 250 | 0.210 |
Why?
|
Lamivudine | 1 | 2024 | 366 | 0.210 |
Why?
|
Oxazines | 1 | 2024 | 350 | 0.200 |
Why?
|
Quality-Adjusted Life Years | 3 | 2024 | 1722 | 0.200 |
Why?
|
Depressive Disorder | 1 | 2015 | 3728 | 0.200 |
Why?
|
Piperidines | 2 | 2021 | 1656 | 0.200 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2014 | 2020 | 0.200 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2024 | 287 | 0.200 |
Why?
|
Atherosclerosis | 1 | 2017 | 3408 | 0.190 |
Why?
|
Tuberculosis | 1 | 2014 | 2017 | 0.190 |
Why?
|
Azathioprine | 1 | 2023 | 354 | 0.190 |
Why?
|
Nucleic Acid Amplification Techniques | 2 | 2021 | 330 | 0.190 |
Why?
|
Bleomycin | 1 | 2022 | 494 | 0.190 |
Why?
|
Drug Utilization | 1 | 2007 | 1188 | 0.190 |
Why?
|
Anthozoa | 1 | 2021 | 66 | 0.190 |
Why?
|
Middle Aged | 23 | 2024 | 220920 | 0.180 |
Why?
|
Etoposide | 1 | 2022 | 634 | 0.180 |
Why?
|
Young Adult | 13 | 2024 | 59255 | 0.180 |
Why?
|
Age Distribution | 2 | 2023 | 2880 | 0.180 |
Why?
|
HIV-1 | 1 | 2017 | 6863 | 0.170 |
Why?
|
Vincristine | 1 | 2022 | 1036 | 0.170 |
Why?
|
Kenya | 1 | 2022 | 758 | 0.170 |
Why?
|
Pseudomonas aeruginosa | 1 | 2007 | 1277 | 0.170 |
Why?
|
Medicare Part D | 1 | 2024 | 355 | 0.160 |
Why?
|
Cross-Sectional Studies | 4 | 2021 | 26127 | 0.160 |
Why?
|
Models, Theoretical | 2 | 2024 | 3575 | 0.160 |
Why?
|
Diabetes Mellitus | 3 | 2024 | 5841 | 0.160 |
Why?
|
Pyridones | 1 | 2024 | 809 | 0.160 |
Why?
|
Immunization, Secondary | 1 | 2021 | 367 | 0.160 |
Why?
|
Nutrition Surveys | 2 | 2023 | 1733 | 0.160 |
Why?
|
Tuberculosis, Cutaneous | 1 | 2018 | 17 | 0.160 |
Why?
|
Africa South of the Sahara | 2 | 2021 | 744 | 0.160 |
Why?
|
Pyrimidines | 2 | 2021 | 3028 | 0.160 |
Why?
|
Aged | 18 | 2024 | 169310 | 0.150 |
Why?
|
Boston | 3 | 2020 | 9326 | 0.150 |
Why?
|
Infant Care | 1 | 2019 | 180 | 0.150 |
Why?
|
Serologic Tests | 1 | 2020 | 381 | 0.150 |
Why?
|
Mycobacterium Infections | 1 | 2018 | 122 | 0.150 |
Why?
|
Encephalitis, Tick-Borne | 1 | 2018 | 41 | 0.150 |
Why?
|
Virology | 1 | 2017 | 75 | 0.140 |
Why?
|
Phylogeny | 3 | 2018 | 2811 | 0.140 |
Why?
|
Encephalitis Viruses, Tick-Borne | 1 | 2018 | 47 | 0.140 |
Why?
|
Leptospirosis | 1 | 2017 | 31 | 0.140 |
Why?
|
Postnatal Care | 1 | 2019 | 262 | 0.140 |
Why?
|
Molecular Typing | 1 | 2017 | 116 | 0.140 |
Why?
|
Remission Induction | 1 | 2023 | 2397 | 0.140 |
Why?
|
Internal Medicine | 1 | 2024 | 1051 | 0.140 |
Why?
|
Mycobacterium | 1 | 2018 | 251 | 0.140 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2020 | 621 | 0.140 |
Why?
|
Retrospective Studies | 9 | 2024 | 80646 | 0.130 |
Why?
|
Urban Population | 2 | 2017 | 2036 | 0.130 |
Why?
|
Escherichia coli | 2 | 2007 | 4217 | 0.130 |
Why?
|
Radiography, Thoracic | 2 | 2020 | 1302 | 0.130 |
Why?
|
Depression | 2 | 2023 | 8124 | 0.130 |
Why?
|
Influenza Vaccines | 1 | 2023 | 768 | 0.130 |
Why?
|
Observation | 1 | 2017 | 310 | 0.130 |
Why?
|
Canada | 1 | 2021 | 2122 | 0.130 |
Why?
|
Housing | 1 | 2020 | 670 | 0.130 |
Why?
|
Budgets | 1 | 2017 | 230 | 0.130 |
Why?
|
Illness Behavior | 1 | 2015 | 23 | 0.130 |
Why?
|
Europe | 1 | 2022 | 3422 | 0.120 |
Why?
|
Universities | 1 | 2020 | 993 | 0.120 |
Why?
|
Cohort Studies | 6 | 2022 | 41493 | 0.120 |
Why?
|
Epidemics | 1 | 2020 | 512 | 0.120 |
Why?
|
Paclitaxel | 1 | 2022 | 1732 | 0.120 |
Why?
|
Aging | 3 | 2024 | 8711 | 0.120 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2020 | 1897 | 0.120 |
Why?
|
Tenosynovitis | 1 | 2014 | 57 | 0.120 |
Why?
|
Internationality | 1 | 2020 | 1001 | 0.120 |
Why?
|
Metagenomics | 1 | 2018 | 467 | 0.110 |
Why?
|
Piperazines | 1 | 2024 | 2523 | 0.110 |
Why?
|
Multivariate Analysis | 3 | 2017 | 12059 | 0.110 |
Why?
|
Amenorrhea | 3 | 2003 | 483 | 0.110 |
Why?
|
Treatment Refusal | 1 | 2017 | 429 | 0.110 |
Why?
|
Health Policy | 2 | 2024 | 2684 | 0.110 |
Why?
|
Ulcer | 1 | 2015 | 204 | 0.110 |
Why?
|
Fever | 3 | 2017 | 1618 | 0.110 |
Why?
|
Liver Cirrhosis | 1 | 2024 | 1935 | 0.110 |
Why?
|
Aged, 80 and over | 8 | 2024 | 58986 | 0.110 |
Why?
|
Research Design | 2 | 2020 | 6180 | 0.110 |
Why?
|
Refugees | 1 | 2021 | 596 | 0.110 |
Why?
|
Mobile Health Units | 1 | 2014 | 92 | 0.100 |
Why?
|
Communicable Diseases | 1 | 2021 | 875 | 0.100 |
Why?
|
Prevalence | 5 | 2024 | 15732 | 0.100 |
Why?
|
Treatment Outcome | 5 | 2019 | 64684 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3086 | 0.100 |
Why?
|
Infant | 4 | 2022 | 36192 | 0.100 |
Why?
|
Dengue | 1 | 2015 | 254 | 0.100 |
Why?
|
Myocardial Ischemia | 1 | 2022 | 2113 | 0.100 |
Why?
|
Dancing | 2 | 2003 | 104 | 0.100 |
Why?
|
Lung | 3 | 2020 | 10002 | 0.100 |
Why?
|
Diagnostic Tests, Routine | 2 | 2014 | 787 | 0.090 |
Why?
|
Child | 7 | 2024 | 80156 | 0.090 |
Why?
|
International Cooperation | 1 | 2017 | 1422 | 0.090 |
Why?
|
Hospitalization | 2 | 2020 | 10721 | 0.090 |
Why?
|
Adolescent | 7 | 2024 | 88324 | 0.090 |
Why?
|
Pregnancy | 3 | 2021 | 29876 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2759 | 0.090 |
Why?
|
Child, Preschool | 3 | 2022 | 42230 | 0.080 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2024 | 2243 | 0.080 |
Why?
|
Equipment Contamination | 1 | 2010 | 182 | 0.080 |
Why?
|
Bone Diseases, Metabolic | 2 | 2003 | 409 | 0.080 |
Why?
|
Risk Factors | 7 | 2019 | 74213 | 0.080 |
Why?
|
Antibodies, Viral | 1 | 2020 | 3156 | 0.080 |
Why?
|
Medicare | 2 | 2024 | 6770 | 0.080 |
Why?
|
Postoperative Complications | 1 | 2011 | 15633 | 0.080 |
Why?
|
Diagnosis, Differential | 4 | 2018 | 12975 | 0.080 |
Why?
|
Incidence | 3 | 2024 | 21355 | 0.080 |
Why?
|
Exercise | 2 | 2021 | 5890 | 0.080 |
Why?
|
Cost Savings | 1 | 2013 | 913 | 0.080 |
Why?
|
Morbidity | 1 | 2013 | 1750 | 0.080 |
Why?
|
Tongue Diseases | 1 | 2008 | 68 | 0.070 |
Why?
|
Oxazolidinones | 1 | 2008 | 98 | 0.070 |
Why?
|
Disease Outbreaks | 1 | 2017 | 1749 | 0.070 |
Why?
|
Public Health | 1 | 2020 | 2669 | 0.070 |
Why?
|
Smoking | 3 | 2020 | 9053 | 0.070 |
Why?
|
Rural Population | 1 | 2017 | 2285 | 0.070 |
Why?
|
Acetamides | 1 | 2008 | 256 | 0.070 |
Why?
|
Telemedicine | 1 | 2024 | 3052 | 0.070 |
Why?
|
Ceftazidime | 1 | 2006 | 57 | 0.070 |
Why?
|
Immunocompromised Host | 1 | 2011 | 857 | 0.060 |
Why?
|
Risk | 1 | 2017 | 9610 | 0.060 |
Why?
|
Genotype | 1 | 2020 | 12990 | 0.060 |
Why?
|
Dideoxyadenosine | 1 | 2024 | 9 | 0.060 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13382 | 0.060 |
Why?
|
Ceftriaxone | 1 | 2006 | 175 | 0.060 |
Why?
|
Diet | 2 | 2021 | 8075 | 0.060 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 15501 | 0.060 |
Why?
|
Microbial Sensitivity Tests | 1 | 2010 | 1937 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2017 | 3600 | 0.060 |
Why?
|
Internship and Residency | 1 | 2024 | 5882 | 0.060 |
Why?
|
Progesterone Congeners | 1 | 2003 | 44 | 0.060 |
Why?
|
Alkynes | 1 | 2024 | 320 | 0.060 |
Why?
|
Prospective Studies | 2 | 2019 | 54426 | 0.060 |
Why?
|
Blood Pressure | 1 | 2019 | 8481 | 0.050 |
Why?
|
Cyclopropanes | 1 | 2024 | 432 | 0.050 |
Why?
|
Benzoxazines | 1 | 2024 | 316 | 0.050 |
Why?
|
Population Density | 1 | 2023 | 193 | 0.050 |
Why?
|
Pseudomonas Infections | 1 | 2007 | 622 | 0.050 |
Why?
|
Obesity | 2 | 2022 | 12947 | 0.050 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2003 | 155 | 0.050 |
Why?
|
RNA, Ribosomal, 16S | 2 | 2018 | 1039 | 0.050 |
Why?
|
Knowledge | 1 | 2024 | 177 | 0.050 |
Why?
|
Immunization Schedule | 1 | 2023 | 227 | 0.050 |
Why?
|
Mental Disorders | 1 | 2022 | 6845 | 0.050 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2003 | 276 | 0.050 |
Why?
|
Developing Countries | 1 | 2014 | 2885 | 0.050 |
Why?
|
DNA, Bacterial | 2 | 2018 | 1479 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2022 | 11461 | 0.050 |
Why?
|
Censuses | 1 | 2022 | 202 | 0.050 |
Why?
|
Anti-Infective Agents | 1 | 2008 | 983 | 0.050 |
Why?
|
Risk Assessment | 1 | 2022 | 23996 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7391 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2010 | 22176 | 0.040 |
Why?
|
Hepatitis B Vaccines | 1 | 2021 | 178 | 0.040 |
Why?
|
Harm Reduction | 1 | 2021 | 144 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2005 | 4853 | 0.040 |
Why?
|
Stroke | 1 | 2022 | 9758 | 0.040 |
Why?
|
Odds Ratio | 2 | 2021 | 9646 | 0.040 |
Why?
|
Treatment Failure | 1 | 2005 | 2644 | 0.040 |
Why?
|
Botswana | 1 | 2022 | 1048 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2020 | 397 | 0.040 |
Why?
|
Mycolic Acids | 1 | 2018 | 54 | 0.040 |
Why?
|
Monte Carlo Method | 1 | 2024 | 1258 | 0.040 |
Why?
|
Rickettsia | 1 | 2018 | 11 | 0.040 |
Why?
|
Drug Combinations | 1 | 2024 | 2048 | 0.040 |
Why?
|
Hemorrhagic Fevers, Viral | 1 | 2018 | 23 | 0.040 |
Why?
|
Base Composition | 1 | 2018 | 290 | 0.040 |
Why?
|
Masks | 1 | 2020 | 208 | 0.040 |
Why?
|
Heart Failure | 1 | 2022 | 11670 | 0.040 |
Why?
|
Hypothalamic Diseases | 1 | 1999 | 134 | 0.040 |
Why?
|
Cote d'Ivoire | 1 | 2017 | 64 | 0.040 |
Why?
|
Bacterial Typing Techniques | 1 | 2018 | 263 | 0.040 |
Why?
|
Infectious Disease Incubation Period | 1 | 2017 | 16 | 0.040 |
Why?
|
False Positive Reactions | 1 | 2020 | 957 | 0.040 |
Why?
|
Calibration | 1 | 2020 | 818 | 0.040 |
Why?
|
Seasons | 1 | 2023 | 1520 | 0.040 |
Why?
|
Indonesia | 1 | 2017 | 128 | 0.040 |
Why?
|
Hospitals | 1 | 2010 | 3882 | 0.040 |
Why?
|
Drugs, Generic | 1 | 2022 | 448 | 0.030 |
Why?
|
Radiography | 2 | 2020 | 6965 | 0.030 |
Why?
|
Italy | 1 | 2018 | 842 | 0.030 |
Why?
|
Patient Care | 1 | 2022 | 622 | 0.030 |
Why?
|
Pandemics | 3 | 2020 | 8656 | 0.030 |
Why?
|
Child, Orphaned | 1 | 2016 | 55 | 0.030 |
Why?
|
Kidney Transplantation | 1 | 2011 | 4235 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2018 | 4740 | 0.030 |
Why?
|
Hyponatremia | 1 | 2018 | 279 | 0.030 |
Why?
|
Nicotine | 1 | 2020 | 680 | 0.030 |
Why?
|
Papillomavirus Vaccines | 1 | 2021 | 496 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.030 |
Why?
|
Neoplasms | 1 | 2024 | 22173 | 0.030 |
Why?
|
Time Factors | 2 | 2007 | 39970 | 0.030 |
Why?
|
Uveitis | 1 | 2018 | 395 | 0.030 |
Why?
|
Tick-Borne Diseases | 1 | 2014 | 36 | 0.030 |
Why?
|
Health Care Rationing | 1 | 2017 | 437 | 0.030 |
Why?
|
Genome, Viral | 1 | 2018 | 667 | 0.030 |
Why?
|
Vasculitis | 1 | 2018 | 521 | 0.030 |
Why?
|
Pancytopenia | 1 | 2014 | 102 | 0.030 |
Why?
|
DNA, Ribosomal | 1 | 2014 | 300 | 0.030 |
Why?
|
Drug Costs | 1 | 2021 | 1183 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2018 | 664 | 0.030 |
Why?
|
Nucleic Acid Hybridization | 1 | 2014 | 1302 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2726 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2014 | 523 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2021 | 2330 | 0.030 |
Why?
|
Models, Biological | 2 | 2020 | 9469 | 0.030 |
Why?
|
Antibodies, Bacterial | 1 | 2018 | 1469 | 0.020 |
Why?
|
Disease Transmission, Infectious | 1 | 2017 | 560 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2020 | 1998 | 0.020 |
Why?
|
Health Expenditures | 1 | 2022 | 2366 | 0.020 |
Why?
|
Headache | 1 | 2017 | 1256 | 0.020 |
Why?
|
Comorbidity | 1 | 2024 | 10508 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2024 | 4016 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2018 | 1589 | 0.020 |
Why?
|
Virus Diseases | 1 | 2014 | 718 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8466 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2014 | 2707 | 0.020 |
Why?
|
Mycobacterium tuberculosis | 1 | 2018 | 1914 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2014 | 1265 | 0.020 |
Why?
|
Color | 1 | 2008 | 299 | 0.020 |
Why?
|
Cause of Death | 1 | 2017 | 3683 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3201 | 0.020 |
Why?
|
Mortality | 1 | 2017 | 2901 | 0.020 |
Why?
|
Biopsy | 1 | 2018 | 6766 | 0.020 |
Why?
|
Health Promotion | 1 | 2017 | 2214 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14666 | 0.020 |
Why?
|
Population Groups | 1 | 2006 | 208 | 0.020 |
Why?
|
Bone Density | 3 | 2003 | 3551 | 0.010 |
Why?
|
Skin | 1 | 2018 | 4484 | 0.010 |
Why?
|
Proteins | 1 | 1999 | 6032 | 0.010 |
Why?
|
Reference Values | 2 | 2002 | 4920 | 0.010 |
Why?
|
Models, Statistical | 1 | 2017 | 5079 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15843 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 17635 | 0.010 |
Why?
|
Puberty, Delayed | 1 | 2002 | 121 | 0.010 |
Why?
|
Survival Analysis | 1 | 2014 | 10090 | 0.010 |
Why?
|
Menarche | 1 | 2003 | 532 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2020 | 26198 | 0.010 |
Why?
|
Wrist Joint | 1 | 2002 | 267 | 0.010 |
Why?
|
Fractures, Stress | 1 | 2002 | 202 | 0.010 |
Why?
|
Logistic Models | 1 | 2014 | 13255 | 0.010 |
Why?
|
Longitudinal Studies | 2 | 2003 | 14607 | 0.010 |
Why?
|
Thyroid Hormones | 1 | 1999 | 404 | 0.010 |
Why?
|
Quality of Life | 1 | 2017 | 13367 | 0.010 |
Why?
|
Spine | 1 | 2002 | 1118 | 0.010 |
Why?
|
Estradiol | 1 | 2002 | 1937 | 0.010 |
Why?
|
Testosterone | 1 | 2002 | 2472 | 0.010 |
Why?
|
Leptin | 1 | 1999 | 1597 | 0.010 |
Why?
|
Animals | 1 | 2021 | 168467 | 0.010 |
Why?
|
Chronic Disease | 1 | 2002 | 9319 | 0.000 |
Why?
|